BIORQ — Biora Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $0.00m
- $35.40m
- $0.00m
Annual income statement for Biora Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 144 | 0.162 | 1.25 | 0.305 | 0.004 |
| Cost of Revenue | |||||
| Gross Profit | 43.5 | 0.162 | 1.25 | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 284 | 119 | 120 | 63.7 | 73.5 |
| Operating Profit | -140 | -119 | -119 | -63.4 | -73.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -149 | -143 | -179 | -49.3 | -124 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -148 | -105 | -179 | -48.8 | -124 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -148 | -193 | -247 | -38.2 | -124 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -229 | -193 | -247 | -38.2 | -124 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1,267 | -891 | -463 | -62.2 | -76.1 |
| Dividends per Share |